# Fluticasone furoate + Umeclidinium + Vilanterol

## Trelegy Ellipta 92/55/22 mcg Inhalation Powder

| TAH Drug Code      | [ETRE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ETRE)                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Chronic obstructive pulmonary disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Oral inhalation: Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily (maximum dose: 1 inhalation/day)                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Hypersensitivity to fluticasone, umeclidinium, vilanterol, or any component of the formulation; severe hypersensitivity to milk proteins                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | 1% to 10%: Headache (4%), voice disorder (>=1%), Diarrhea (2%), dysgeusia (2%), constipation (>=1%), oral candidiasis (>=1%), gastroenteritis (1%), Urinary tract infection (>=1%), Influenza (>=1%), Back pain (4%), arthralgia (>=1%), Pneumonia (8%), bronchitis (>=1%), pharyngitis (>=1%), rhinitis (>=1%), sinusitis (>=1%), upper respiratory tract infection (>=1%), cough (1%), oropharyngeal pain (1%) Frequency not defined:Paradoxical bronchospasm <1%, postmarketing, and/or case reports: Anaphylaxis |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/fluticasone-furoate-and-umeclidinium-and-vilanterol-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                   |

